Vertex is executing a multi-year transition to SaaS, evidenced by 10.5% YoY revenue growth in Q2 2026 and deferred revenue expansion to $386.9M, which supports durable subscription revenue. However, the company's profitability remains strained, with operating ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | $0.20+4.8% vs $0.19 | $204M+0.9% vs $202M |
Q2 2026 May 7, 2026 | $0.17+6.3% vs $0.16 | $197M+0.9% vs $195M |
Q1 2026 Feb 11, 2026 | $0.17+0.0% vs $0.17 | $195M+0.2% vs $194M |
Q4 2025 Nov 3, 2025 | $0.17+0.0% vs $0.17 | $192M-1.1% vs $194M |
AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.
Vertex Pharmaceuticals NASDAQ: VRTX is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company's priorities, CEO and President Reshma Kewalramani said at Morgan Stanley's 24th Annual Healthcare Conference.
Vertex Pharmaceuticals NASDAQ: VRTX highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a Wells Fargo healthcare conference appearance.
Vertex Pharmaceuticals NASDAQ: VRTX outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal product launch efforts and upcoming pipeline milestones across kidney disease, pain, cystic fibrosis and rare endocrine disorders.
Benchmark VERX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Vertex, Inc. (VERX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.72 | $1.9B | 293.00 | 12.25% | 0.96% | 3.29% | — | |
| $0.98 | $4.67M | -0.02 | -29.45% | -267.2% | — | — | |
| $36.17 | $10.07B | 76.96 | 21.28% | 5.84% | 15.93% | — | |
| $286.80 | $78.45B | 20.98 | 15.63% | 21.29% | 23.42% | — | |
| $263.68 | $105.4B | 24.08 | 6.74% | 20.11% | 70.2% | — | |
| $143.58 | $7.69B | 29.18 | 11.04% | 15.23% | 23.44% | — |
Vertex, Inc. (VERX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Vertex, Inc. (VERX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Jun 11, 2026·SEC
May 7, 2026·SEC
Get notified when VERX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Vertex, Inc. (VERX) stock FAQ — growth, dividends, profitability & financials explained
Vertex, Inc. (VERX) reported $787.4M in revenue for fiscal year 2025. This represents a 189% increase from $272.4M in 2018.
Vertex, Inc. (VERX) grew revenue by 12.2% over the past year. This is steady growth.
Yes, Vertex, Inc. (VERX) is profitable, generating $3.6M in net income for fiscal year 2025 (1.0% net margin).
Vertex, Inc. (VERX) has a return on equity (ROE) of 3.3%. This is below average, suggesting room for improvement.
Vertex, Inc. (VERX) generated $58.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
